Treatment Information

Rubraca (Rucaparib) Shrank Tumors in Nearly Half of Advanced Prostate Cancer Patients with BRCA Mutations.

Rubraca (rucaparib), Clovis Oncology‘s oral PARP inhibitor, shrank tumors in 44% of metastatic hormone-resistant prostate cancer (mCRPC) patients with BRCA mutations included in the Phase 2 TRITON2 clinical trial. The treatment, which is already approved for ovarian cancer, also reduced PSA levels — a biomarker of prostate cancer — in 51.1% of patients with BRCA more »

Some Advanced Prostate Cancer Patients May Respond Well to Keytruda Immunotherapy.

Immunotherapy with Keytruda (pembrolizumab) may be an effective way to treat some cases of advanced prostate cancer according to a preliminary study conducted at Oregon Health and Science University – Knight Cancer Institute. Findings were published in the journal Oncotarget in a paper entitled “Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.” Keytruda is a more »

Phase 2 Trial of Potential Prostate Cancer Vaccine, ProscaVax, Soon to Enroll Early-Stage Patients

OncBioMune Pharmaceuticals will soon start a Phase 2 clinical trial of its investigational vaccine ProscaVax in men with early-stage prostate cancer under “active surveillance”. ProscaVax consists of a combination of the PSA protein produced by the prostate gland with the cytokines interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF). [Cytokines are molecules that participate in more »

Both Enzalutamide and Apalutamide Delay Prostate Cancer Progression in Men with Non-Metastatic Hormone-Resistant Prostate Caancer

In catching up on some news from a few months ago, I realized that much had been written recently about treating men with an early stage of advanced  prostate cancer. So here is some information in addition to the following posts; The FDA Approves Apalutamide for Some Men with Prostate Cancer; and  Xtandi Extends Metastasis-Free Survival in more »

The FDA Approves Apalutamide for Some Men with Prostate Cancer

I realize this is somewhat old news but I’d like to share it anyway. On February 14, the Food and Drug Administration (FDA) approved apalutamide (Erleada) for men with prostate cancer that has not spread (non-metastatic) and is resistant to standard hormone therapy, also called androgen deprivation therapy (ADT). In the clinical trial that led to its approval, more »

Xtandi Extends Metastasis-Free Survival in Hormone-Resistant Men with Rising PSA according to Phase 3 Study.

Men with nonmetastatic, castration (hormone)-resistant prostate cancer (CRPC) and a rapidly rising prostate-specific antigen (PSA) level are at high risk for metastasis. Currently, only one recently approved treatment, Erleada® (apalutamide), is available to these patients. Xtandi®, an androgen receptor inhibitor, is an approved treatment for metastatic CRPC patients. It has been shown to delay disease progression and prolong more »

Immunotherapy: How the Immune System Fights Cancer

The National Cancer Institute (NCI), the largest institute of the National Institutes of Health (NIH), recently posted a short (3-4 minute) but very illustrative video showing and describing three ways how our immune system fights cancer. These methods include: a) non-specific immune stimulation, as illustrated in bladder cancer; b) T-cell transfer therapy, somewhat similar to how more »

PARP Inhibitors and Prostate Cancer- Keeping Cancer Cells From Repairing Themselves

Drugs targeting poly (ADP-ribose) polymerase (PARP) are helping patients battle back more effectively against cancer. An enzyme, PARP helps repair damaged DNA in cells, and while that’s a good thing in healthy people, it can be bad news for cancer patients. To prevent PARP from repairing DNA breaks in cancer cells, AstraZeneca developed Lynparza, a PARP inhibitor (PARPi) more »

Zytiga (Abiraterone) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer

On February 8th, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Zytiga® (abiraterone acetate) in combination with prednisone for the treatment of patients with metastatic high-risk hormone-sensitive prostate cancer (HSPC). The approval is based on Phase 3 data from the pivotal more »

Apalutamide (ARN-509) Approved to Treat Non-Metastatic, Hormone-Resistant Prostate Cancer

On Feb. 14th, the U.S. Food and Drug Administration approved apalutamide (Erleada®, previously  called ARN-509) for the treatment of non-metastatic, castration (hormone)-resistant prostate cancer (CRPC). Apalutamide could be administered in a clinical setting wherein men who are being treated with androgen (hormone) deprivation therapy (ADT) see their PSA levels begin to rise, but no metastases more »

A Phase 3 Trial Shows that Xtandi Reduces the Risk of Metastasis in Hormone-Resistant Prostate Cancer

According to results just recently presented at the February 2018 Genitourinary Cancers Symposium in San Francisco, treatment with Xtandi® (enzalutamide) reduced the risk of metastasis or death in hormone-resistant prostate cancer (CRPC) patients whose cancer has not yet spread beyond the prostate, Pfizer and Japan-based Astellas Pharma recently announced. The Phase 3 PROSPER clinical trial more »

Positive Early-Stage Study Results of ProstaVax, Another Prostate Cancer Vaccine.

OncBioMune’s investigational cancer vaccine ProscaVax reduced tumor growth in 70% of prostate cancer patients included in a Phase 1a study. The immunotherapy candidate consists of a combination of the PSA protein (a hallmark of prostate cancer) with the cytokines — molecules produced by immune cells — interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). The clinical trial (NCT02058680)  is evaluating the safety more »

Enzalutamide (Xtandi) Delays Metastasis in Hormone-Resistant Prostate Cancer

Adding Xtandi® (enzalutamide) to hormone therapy reduces the risk of cancer spreading in patients with non-metastatic, hormone-resistant prostate cancer (CRPC), new Phase 3 trial data shows. Additional results were announced by Pfizer and Astellas Pharma, the drug developers. “Many prostate cancer patients who initiate hormone therapy will experience disease progression illustrated by a rising PSA level, and currently, more »

Apalutamide (ARN-509), a Potential New Therapy for Non-Metastatic Hormone-Resistant Prostate Cancer.

Janssen-Biotech has submitted a new drug application to the Food and Drug Administration (FDA) for apalutamide (ARN-509) to treat non-metastatic hormone-resistant prostate cancer. Apalutamide is an oral androgen receptor inhibitor that blocks the action of testosterone in prostate cancer cells. (Whether ARN-509 differs in its mechanism of action from enzalutamide [Xtandi] is not known to this more »

Am I On the Right Track? Encouraging Good News on Nivolumab (Opdivo)

In December 2016, when I first embarked on my latest course of prostate cancer treatments, it seemed logical to me to treat the cancer first by stimulating my immune system; therefore, Provenge® (sipuleucel-T) was my first choice. That course of three treatments were administered quite readily. Immediately after receiving Provenge®, I was unexpectedly made aware more »

Bad News and Then Good News Next.

For men with metastatic, hormone-resistant prostate cancer, treatment with Taxotere (docetaxel) and prednisone has been shown to  improve survival. But few treatment strategies are available if this first-line therapy fails. Second-line therapy of anti-cancer agent Jevtana with the steroid medicine prednisone is currently used, with favorable data reported in 2010. However, new options are still more »